Lilit Baltaian
Tujunga, CANPI 1154552305
Payments from drug & device makers
Across 180 payments — averaging $18.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$685
- AbbVie$480
- AstraZeneca$294
- Takeda Pharmaceuticals U.S.A., Inc.$268
- Pfizer$228
- Novo Nordisk$162
- plus $1K from 22 others
What the payments were for
- Food & beverage$3,282100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 33 | $685 |
| AbbVie(2 entities) | 28 | $480 |
| AstraZeneca | 13 | $294 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $268 |
| Pfizer | 15 | $228 |
| Novo Nordisk | 16 | $162 |
| Lilly USA, LLC | 6 | $156 |
| Sumitomo Pharma America, Inc. | 7 | $137 |
| Sanofi-aventis U.S. LLC | 6 | $125 |
| Ironwood Pharmaceuticals, Inc | 5 | $88 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $72 |
| Nestle Healthcare Nutrition Inc. | 3 | $68 |
| Biohaven Pharmaceuticals, Inc. | 3 | $64 |
| Scilex Pharmaceuticals Inc. | 4 | $54 |
| Redhill Biopharma Inc. | 2 | $52 |
| Exact Sciences | 2 | $49 |
| E.r. Squibb & Sons, L.L.C. | 3 | $41 |
| Teva Pharmaceuticals USA, Inc. | 2 | $38 |
| Eyevance Pharmaceuticals LLC | 2 | $30 |
| Hikma Pharmaceuticals USA | 2 | $30 |
| GSK | 2 | $29 |
| Johnson & Johnson | 1 | $24 |
| IBSA Pharma Inc. | 1 | $22 |
| Bayer | 1 | $21 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $20 |
| Abbott | 1 | $19 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
| Alfasigma USA, Inc. | 1 | $12 |
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 166 | $162,426 |
| Diclofenac Potassium | 82 | $141,986 |
| CreonLipase/Protease/Amylase | 151 | $136,927 |
| JanuviaSitagliptin Phosphate | 141 | $83,871 |
| VascepaIcosapent Ethyl | 230 | $79,931 |
| LinzessLinaclotide | 139 | $75,582 |
| Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate | 66 | $55,188 |
| FarxigaDapagliflozin Propanediol | 91 | $51,286 |
| Icosapent Ethyl | 245 | $47,126 |
| MounjaroTirzepatide | 46 | $45,254 |
| Repatha SureclickEvolocumab | 68 | $37,572 |
| JardianceEmpagliflozin | 47 | $30,459 |
| JanumetSitagliptin Phos/Metformin Hcl | 43 | $28,890 |
| Metformin Hcl | 403 | $28,364 |
| EliquisApixaban | 43 | $27,927 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess, Restasis | $480 | $224,725310 claims |
| Novo NordiskOzempic | $162 | $162,426166 claims |
| Lilly USA, LLCMounjaro, Trulicity | $156 | $58,35961 claims |
| AstraZenecaFarxiga | $294 | $51,28691 claims |
| AmgenEvenity (2 Syringes), Prolia | $685 | $44,50322 claims |
| PfizerEliquis | $228 | $27,92743 claims |
| Johnson & JohnsonXarelto | $24 | $27,62329 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Dexilant | $268 | $6,31722 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in Californiaon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.